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Abstract 
Objective.  To investigate the role of Junctional adhesion molecule A (JAM-A) in the 
pathogenesis of systemic sclerosis (SSc). 
Methods.  Biopsies from proximal and distal arm skin and serum were obtained from patients 
with SSc and normal (NL) volunteers. To determine the expression of JAM-A on SSc dermal 
fibroblasts and in SSc skin, cell surface ELISAs and immunohistology were performed. An 
ELISA was designed to determine the amount of soluble JAM-A (sJAM-A) in serum. Myeloid 
U937 cell-SSc dermal fibroblast and skin adhesion assays were performed to determine the role 
of JAM-A in myeloid cell adhesion. 
Results.  The stratum granulosum and dermal endothelial cells (ECs) from distal arm SSc skin 
exhibited significantly decreased expression of JAM-A compared to NL. However, sJAM-A was 
elevated in the serum of patients with SSc compared to NL. Conversely, JAM-A was increased 
on the surface of SSc compared to NL dermal fibroblasts. JAM-A accounted for a significant 
portion of U937 binding to SSc dermal fibroblasts. In addition, JAM-A contributed to U937 
adhesion to both distal and proximal SSc skin. 
Conclusions.  JAM-A expression is dysregulated in SSc skin.  Decreased expression of JAM-A 
on SSc ECs may result in a reduced response to proangiogenic basic fibroblast growth factor.  
While increased JAM-A expression on SSc fibroblasts may serve to retain myeloid cells, which 
in turn secrete angiogenic factors. 
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 The pathogenesis of systemic sclerosis (SSc) is complex and remains incompletely 
understood, however fibroblasts, monocytes, and endothelial cells (ECs) seem to be key players.  
These cells facilitate excessive synthesis of extracellular matrix proteins and deposition of 
increased amounts of collagen, immune activation, and vascular damage, all of which are known 
to be important in the development of this illness.[1] 
 Adhesion molecules play multiple roles in angiogenesis.  Specific adhesion molecule 
expression can mediate angiogenesis indirectly by promoting the migration of monocytes.[2]  
These monocytes are then capable of becoming tissue macrophages and secreting angiogenic 
factors.  Cellular adhesion molecules may have a role in the immunopathogenesis of SSc.[3]  We 
and others have shown that several adhesion molecules are overexpressed in SSc skin.[4, 5]  A 
number of soluble adhesion molecules are also elevated in SSc.[3] 
 JAM-A has been implicated in a variety of physiologic and pathologic processes 
involving cellular adhesion, tight junction assembly, and leukocyte transmigration.[6, 7]  JAM-A 
facilitates leukocyte adhesion and transmigration through its interaction with lymphocyte 
function–associated antigen 1 (LFA-1).  Recently, JAM-A has been shown to play a role in 
angiogenesis.[8] 
 As SSc is characterized by both inflammatory cell infiltration and vasculopathy, we 
hypothesized that JAM-A may play a role in its pathogenesis.  Here we demonstrate aberrant 
expression of JAM-A in SSc skin and sJAM-A in SSc serum.  Moreover, we show a novel role 
for JAM-A in mediating myeloid cell adhesion to SSc skin. 
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Materials and methods 
Patients and controls.  Skin punch biopsies and peripheral blood samples were obtained from 
subjects with SSc (all with diffuse disease) and control subjects. All SSc patients fulfilled the 
American College of Rheumatology criteria for SSc and also met the criteria for diffuse SSc.[1, 
9]  Biopsies were taken with full informed consent, and this study was approved by the 
Institutional Review Board. 
Immunohistology.  We performed immunohistologic staining on cryosections from SSc and 
normal skin, as described previously.[10] Goat anti-human JAM-A antibody (R&D Systems, 
Minneapolis, MN) was used as a primary antibody. The slides were read by a pathologist under 
blinded conditions. For JAM-A staining, the percentage of positive cells was calculated semi-
quantitatively as stained cells in proportion to all cells of a distinctive subset. We also used a 
similar method with an anti-von Willebrand factor antibody to identify endothelial cells. Blood 
vessels were scored using a scale of: 0=avascular; 1=slight decrease; 2=normal; 3=slight 
increase; 4=marked increase. 
Immunofluorescence.  We performed immunofluorescence on cryosections from SSc and 
normal skin.  Sections were fixed with 4% formalin and blocked with 20% fetal bovine serum 
and 5% donkey serum.  Goat anti-human JAM-A antibody (R&D Systems) and mouse anti-
human Von Willebrand factor (vWF) (Dako, Denmark) were used as primary antibodies.  
Fluorescent conjugated secondary antibodies were purchased from Molecular Probes (Eugene, 
OR).  4',6-diamidino-2-phenylindole (DAPI) was used to stain cell nuclei.  Images were taken at 
400x. 
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Cell lysis and western blotting.   NL and SSc dermal fibroblast cell lines were established as 
described previously.[11] Cell lysis and western blotting were performed as described.[10] 
Membranes were probed with anti-human JAM-A antibody (R&D Systems). Densitometric 
analysis of the bands was performed using UN-SCAN-IT software, version 5.1 (Silk Scientific).  
Cell surface ELISA. Cell surface ELISAs were performed as previously described.[10] Dermal 
fibroblasts were plated in 96-well plates, stimulated with tumor necrosis factor-alpha (TNF-α), or 
interleukin-1β (IL-1β), or interferon-γ (IFN-γ) (all 25 ng/ml, R&D Systems) or incubated in 
serum free RPMI for 24 hours. The fibroblasts were incubated with anti-human JAM-A antibody 
(R&D Systems) or goat IgG. 
Human dermal microvascular endothelial cell (HMVEC) cell culture.  HMVECs were 
obtained from Lonza (Basel, Switzerland) and cultured using EBM complete media (Lonza).  
The cells were serum starved overnight and then stimulated with either TNF-α or IL-1β.  
Supernatants were collected and concentrated using Amicon ultra filters (Millipore). 
Serum JAM-A ELISA. Ninety six well microplates were coated with anti-human JAM-A 
antibody (R&D Systems) and blocked with 1% bovine serum albumin in PBS. Sample or 
standards (R&D Systems) was added, followed by the addition of mouse anti-human JAM-A 
antibody (Santa Cruz, Santa Cruz, CA), anti-mouse biotinylated  antibody (Vector Laboratories), 
streptavidin-HRP (R&D Systems), TMB substrate solution, and 2N H2SO4. The absorbance of 
each well read using a microplate reader at 450/570 nm.  The diction limit of the sJAM-A ELISA 
was 0.3 ng/ml. 
U937 cell-fibroblast adhesion assay. Adhesion assays were performed as previously described 
using myeloid U937 cells.[10] These cells are human histiocytic lymphoma cells that are 
myeloid.  Combinations of JAM-A neutralizing antibody (Santa Cruz), mouse antibody to human 
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CD11a (GeneTex Incorporated), neutralizing mouse anti-human ICAM-1 antibody (R&D 
Systems), or mouse IgG were used.  The inhibitory effect of neutralizing antibody treatment was 
given as the percentage of maximal binding, which was defined as the number of adherent cells 
in the control antibody treated sections. 
Stamper-Woodruff adhesion assay.  In situ assays were performed as previously 
described.[10] JAM-A neutralizing antibody (R&D Systems) or goat IgG control were added to 
the skin sections.U937 cells were labeled with Calcein-AM fluorescent dye (5 µM, Invitrogen) 
and added to the sections and incubated for 1 hour in the dark.  Non-adherent cells were washed 
off.  The total number of fluorescence-labeled U937 cells was counted by a blinded observer 
using a fluorescence microscope. The inhibitory effect of the anti-JAM-A antibody was given as 
the percentage of maximal binding, which was defined as the number of adherent cells in the 
control antibody treated sections. 
Statistical analysis.  Student’s t-tests were performed, and P values less than 0.05 were 
considered significant. All values presented were the mean ± standard error of the mean (SEM).  
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Results 
Patient characteristics.  The SSc group consisted of 18 females and 2 males (52.5 ± 1.8 years), 
while the NL control group consisted of 7 males and 3 females (51.2 ± 4.4 years).  The mean 
disease duration of the SSc group was 3.7 ± 0.8 years.  Punch biopsies were taken from clinically 
less involved proximal arm skin (mean skin score 1.2 ± 0.2) and involved distal forearm skin 
(2.0 ± 0.2).  The proximal biopsy site was far away from the leading edge of the distal area. 
SSc distal arm skin had significantly fewer blood vessels compared to NL skin. Our work 
confirmed that in our patient population SSc distal arm skin has significantly fewer blood vessels 
(blood vessel score=1.7) compared to NL skin (blood vessel score=2.0, p<0.05) (figure 1).[12]  
In addition, we found that SSc proximal arm skin (blood vessel scale score=1.9) had a blood 
vessel score between that of SSc distal skin and NL skin. 
JAM-A is abnormally expressed in SSc skin.  JAM-A expression in normal and SSc skin was 
evaluated using immunohistology and immunofluorescence.  JAM-A is expressed on dermal 
ECs, fibroblasts, macrophages, and in the epidermis (figure 2).  Moreover, dual 
immunofluorescence using anti-JAM-A and anti-vWF antibodies further indicated that JAM-A is 
expressed on dermal ECs.  As shown in figure 2I, quantification of JAM-A immunohistology 
demonstrated that SSc dermal ECs exhibited significantly decreased expression of JAM-A (mean 
of 71%) compared to NL controls (mean of 93%, p<0.05).  In addition, JAM-A was less 
expressed in the stratum granulosum of the epidermis of distal SSc skin (mean of 50%) 
compared to NL skin (mean of 98%, p<0.05, figure 2J).  In contrast, SSc dermal perivascular 
macrophages expressed increased levels of JAM-A (12% in distal skin and 18% in proximal 
skin) compared to NL skin (mean of 4%, both p<0.05) (data not shown).  Similarly, SSc 
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subepidermal macrophages expressed increased levels of JAM-A (mean of 8% in distal skin and 
mean of 8% in proximal skin) compared to NL skin (mean of 3%, both p<0.05) (data not shown). 
JAM-A was more highly expressed on SSc dermal fibroblasts vs. NL dermal fibroblasts.  
JAM-A was more highly expressed on dermal SSc compared to NL fibroblasts (figure 3A). 
Western blotting resulted in similar results (figure 3B). However, the expression of JAM-A on 
either SSc or NL dermal fibroblasts was not inducible by TNF-α, IFN-γ, or IL-1β (data not 
shown). 
Elevated sJAM-A in SSc serum. A sJAM-A ELISA was designed, and serum JAM-A was 
detected in all normal volunteers and SSc patients.  The concentration of sJAM-A in the serum 
of patients with SSc was 2.4 ± 0.4 ng/ml, whereas the concentration for NL controls was 1.0 ± 
0.2 ng/ml (p<0.05) (figure 4).  
sJAM-A is secreted by ECs.  sJAM-A was detectable in the culture supernatant of HMVECs.  
Moreover, stimulation with TNF-α resulted in a significant increase of sJAM-A in HMVEC 
culture supernatants. 
JAM-A mediates myeloid U937 cell binding to SSc dermal fibroblasts. We found that SSc 
dermal fibroblasts bound a greater number of myeloid U937 cells than NL dermal fibroblasts 
(p<0.05) (data not shown).  Moreover, JAM-A accounted for a significant portion of U937 
binding to SSc dermal fibroblasts.  U937 binding to SSc dermal fibroblasts was inhibited by 
neutralizing anti-JAM-A antibody treatment (86% of maximal binding, p<0.05) (figure 5). 
Neutralizing antibody against the JAM-A ligand LFA-1 also inhibited U937 cell binding to SSc 
dermal fibroblasts (90% of maximal binding, p<0.05).  Similarly, neutralizing antibody against 
the LFA-1 receptor ICAM-1 inhibited U937 cell binding to SSc dermal fibroblasts (83% of 
maximal binding).  A combination of neutralizing antibodies against JAM-A, LFA-1, and 
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ICAM-1 resulted in the greatest inhibition of U937 cell binding to SSc dermal fibroblasts (73% 
of maximal binding). 
 JAM-A contributes to U937 cell adhesion to SSc skin. We found that similar to the results of 
the U937-fibroblast in vitro adhesion assay, anti-JAM-A neutralizing antibody decreased U937 
cell binding to SSc skin (figure 6).  U937 cell binding to SSc proximal arm skin (44% of 
maximal binding, p<0.05) and distal forearm skin (61% of maximal binding, p<0.05) was 
inhibited by anti-JAM-A antibody treatment.  Collectively these results indicate that JAM-A 
plays an important role in myeloid cell adhesion to SSc skin. 
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Discussion 
 The etiology and pathogenesis of SSc remains unknown. Nonetheless, signs of vascular 
injury and devascularization of involved organs in association with evidence of profound 
endothelial dysfunction are well documented. Adhesion molecules, molecules known to promote 
both inflammatory cell infiltration and angiogenesis, may play a role in the pathogenesis of 
SSc.[3] 
 Our results demonstrated that dermal ECs from SSc skin exhibit decreased expression of 
JAM-A compared to ECs in NL skin. Decreased JAM-A expression increases permeability. 
Blocking JAM-A expression caused a decrease in neutrophil and monocyte extravasation in 
several models including inflammatory meningitis, peritonitis, and ischemia-reperfusion 
injury.[13-16] These findings suggest that the downregulation of JAM-A expression on SSc 
dermal ECs may effect the influx of leukocytes into SSc skin. 
 In addition, JAM-A is a proangiogenic adhesion molecule.  JAM-A forms a complex 
with integrin αvβ3 and mediates basic fibroblast growth factor (bFGF) induced angiogenesis.[8]  
JAM-A overexpression on ECs induces both EC proliferation and migration on vitronectin.  In 
addition, inhibition of JAM-A signaling blocks bFGF-induced EC proliferation, tube formation 
and in vivo angiogenesis.[8, 17]  Our results demonstrate that JAM-A is downregulated on SSc 
dermal ECs, and therefore may not be able to respond to bFGF and mediate angiogenesis. 
 Soluble adhesion molecules have also been shown to be elevated in patients with SSc. 
Recently, Cavusoglu et al. observed significantly higher levels of plasma sJAM-A in patients 
with advanced coronary artery disease and indicated that JAM-A may be an important mediator 
of the effects of inflammation on the vessel wall.[18]  Our results show that the concentration of 
sJAM-A in the serum of patients with SSc is elevated compared to NL serum. Moreover, we 
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demonstrated that sJAM-A can be secreted by cultured ECs.  This is the first study to suggest a 
link between serum sJAM-A concentration and SSc, and further study is needed to determine if 
the concentration of serum sJAM-A correlates with additional clinical manifestations of SSc. 
 Previous studies have shown that SSc peripheral blood mononuclear cells (PBMCs) and 
SSc dermal fibroblasts are hyperadhesive.[19] Here we found that JAM-A is overexpressed on 
SSc dermal fibroblasts and mediates the adhesion of myeloid U937 cells to both SSc dermal 
fibroblasts and proximal and distal SSc skin.  As myeloid cells mature into monocytes and 
macrophages that have the potential to secrete a variety of angiogenic factors, our results have 
particular importance to the pathogenesis of SSc. 
 Our study suggests that JAM-A plays multiple roles in the pathogenesis of SSc.  The 
reduced expression of JAM-A on the surface of ECs may contribute to dysregulated 
angiogenesis in SSc skin, as JAM-A EC expression is required for bFGF induced 
angiogenesis.[8, 20, 21]  Moreover, the elevated SSc serum levels of sJAM-A could be the result 
of the characteristic EC injury in SSc, further strengthening the suggestion of JAM-A as a 
vascular disease marker.[18]  In contrast, JAM-A exemplifies the dual nature of an adhesion 
molecule, as our results demonstrate its importance in mediating myeloid cell retention in SSc 
skin.  Collectively, these results suggest that JAM-A is dysregulated on multiple cell types in 
SSc, and that further study on its role in SSc skin angiogenesis is warranted. 
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Figure Legends 
 
Figure 1.  Distal SSc skin has fewer blood vessels than NL skin. n = the number of patients.  
Figure 2.  Immunohistological and immunofluorescence analysis of JAM-A on NL and SSc 
skin. Representative photos of JAM-A immunohistological staining in endothelial cells of NL 
skin (A), proximal SSc skin (B), distal SSc skin (C), and of the isotype control (D) are shown, all 
at 200x.  Arrows indicate positive JAM-A staining of vasculature. Representative photos of dual 
immunofluorescence staining of JAM-A (green) and vWF (red) in NL skin (E), proximal SSc 
skin (F), distal SSc skin (G), and of the isotype control (H) are shown, all at 400x.  Arrows 
indicate dermal blood vessels. (I) Dermal ECs from proximal and distal SSc skin exhibited 
decreased expression of JAM-A compared to NL skin.  (J) JAM-A was less expressed in the 
stratum granulosum of SSc skin compared to NL skin. n = the number of patients.  
Figure 3.  JAM-A is overexpressed on SSc dermal fibroblasts. JAM-A is overexpressed on SSc 
dermal fibroblasts compared to NL dermal fibroblasts (Fig 3A).   A representative western blot is 
shown in Fig 3B, expression of JAM-A protein is higher in SSc dermal fibroblasts. n = the 
number of different SSc patient or NL volunteer derived fibroblast cell lines.  
Figure 4.  sJAM-A is elevated in the serum of SSc patients and secreted by HMVECs. The 
concentration of sJAM-A in SSc serum was significantly greater compared to NL control serum 
(Fig 4A). n=the number of patients.  sJAM-A is found in the culture supernatants of HMVECs 
(Fig 4B), and its expression is increased with stimulation by TNF-α.n=the number of replicates.   
Figure 5.  JAM-A mediates adhesion of U937 cells to SSc dermal fibroblasts. U937 binding to 
SSc dermal fibroblasts was inhibited by anti-JAM-A antibody and anti-LFA-1 antibody (Fig 
5A).  U937 cell binding to SSc dermal fibroblasts was inhibited by anti-ICAM-1 antibody and a 
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combination of anti-ICAM-1, LFA-1, and JAM-A antibodies.  n = the number of different 
fibroblast cell lines from SSc patients.  
Figure 6.  JAM-A mediates adhesion of U937 cells to SSc skin. A, U937 binding to SSc 
proximal arm skin and distal arm skin sections was inhibited by anti-JAM-A antibody treatment.  
Representative photos of the effect of anti-JAM-A on U937 cell adhesion to proximal SSc skin 
(B), distal SSc skin (C), and in the presence IgG control in place of anti-JAM-A (D) are shown, 
all at 100x. n=the number of patients. 
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Figure 1 
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Figure 2 I-J 
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                                                         Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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